Pharmaceuticals
Finance professionals in Pharmaceuticals
These ten finance professionals have held finance director, VP of finance, FP&A, R&D finance, controller and accounting roles at pharmaceutical companies. A reader can learn how pharma finance teams plan R&D and commercial budgets, forecast product performance and weigh portfolio investment decisions.
Professionals to explore
01—10Carolina Cambra
LinkedInExperience: Corporate Head of FP&A · Incyte
Corporate Head of FP&A at Incyte since 2025. The highlight cites 24+ years of global pharmaceutical experience across R&D, commercial and manufacturing. Other listed roles include VP Global Finance Novartis Institutes of Biomedical Research at Novartis (2021–2025), Global Head Finance Cell&Gene Tech Dev Manufacturing at Novartis (2019–2021), Executive Director Finance Commercial Oncology (head BPA) at Novartis (2015–2019) and Head of Global Program Finance at Novartis (2012–2015).
Cindy Pearlstein
LinkedInExperience: Senior Director of Accounting · Sunovion Pharmaceuticals
Senior Director of Accounting at Sunovion Pharmaceuticals since 2021. The highlight cites commercial finance business partnering, controlling, FP&A and accounting and reporting experience in a billion-dollar biotechnology and pharmaceutical sales and marketing organization. Other listed roles include Head of US Immunology Controlling at Sanofi (2017–2021), Fertility and Endocrinology Controller at EMD Serono, Inc. (2015–2017), Director of Accounting & Reporting at EMD Serono, Inc. (2006–2015) and Assistant Controller Neurology at EMD Serono, Inc. (2004–2006).
Enda Wiseman
LinkedInExperience: Senior Finance Director - Head of R&D Finance · ViiV Healthcare
Senior Finance Director - Head of R&D Finance at ViiV Healthcare since 2025. The highlight describes more than 20 years of pharmaceutical finance experience spanning R&D Finance, Commercial Finance and Trading Partner Finance, and partnering with R&D leadership on portfolio prioritization. Other listed roles include Senior Finance Director - US Anti Infectives & Respiratory & Gross To Net Strategy at GSK (2022–2025) and Senior Finance Director - US Specialty & Market Access & Respiratory at GSK (2021–2022).
Hans Mueller
LinkedInExperience: Director Global Clinical Development Finance · Merck
Former Director Global Clinical Development Finance at Merck (2014–2022). The highlight describes being finance lead for a team supporting FP&A for a global research organization with more than 2 billion in annual operating budget. Other listed roles include GCD Strategy Lead GCTO Finance Lead at Merck (2022–2024), Director MRL Finance at Merck (2009–2014), Director Business Integration at Merck (2007–2009) and Associate Director, External Services at Merck (2006–2007).
Jeroen Lamers
LinkedInExperience: Director, Finance & Accounting · Ferring Pharmaceuticals
Director, Finance & Accounting at Ferring Pharmaceuticals since 2020. The highlight mentions working 10+ years in the pharmaceutical industry as a finance professional in the Netherlands, France, Switzerland and the US. Other listed roles include Associate Director, U.S. R&D FP&A at Ferring Pharmaceuticals (2018–2020), Regional Internal Control Responsible, R&D and North America at Ferring Pharmaceuticals (2016–2019), Senior Manager, Finance at Ferring Pharmaceuticals (2018) and Finance Manager at Ferring Pharmaceuticals (2014–2017).
Margaret Kilian
LinkedInExperience: Head of Financial Planning & Analysis (FP&A), Global R&D · UCB
Head of Financial Planning & Analysis (FP&A), Global R&D at UCB since 2024. Other listed roles include Director - R&D Portfolio Valuation & Planning Finance Business Partner Epilepsy R&D at UCB (2022–2024), Head of Strategic Operations & Chief of Staff - Seizure Freedom Mission at UCB (2021–2022), Finance Business Partner - R&D Global Neurology Missions at UCB (2020–2021) and Head of US Financial Planning & Analysis (FP&A) at UCB (2018–2020).
Ruiling Hartley
LinkedInExperience: VP of Finance, finance head for US Operation · BE Pharmaceuticals, Inc.
Former VP of Finance, finance head for US Operation at BE Pharmaceuticals, Inc. (2019–2022). The highlight describes finance leadership across pharma R&D, manufacturing, end-to-end supply chain and commercialization. Also R&D Finance at Vertex Pharmaceuticals since 2025. Other listed roles include Global Head of Finance, Business Partner at Emerald Clinical (2024–2025), Exec Director, Global FP&A, Portfolio and BD&L Analytics at Zai Lab (2022–2024) and US Pharma Gross to Net Finance Partner at GSK (2018–2019).
Ryan Clarke
LinkedInExperience: FD, UK Pharma Planning & Performance · GSK
FD, UK Pharma Planning & Performance at GSK since 2025. The highlight cites skills in internal audit, financial control, FP&A and partnering across R&D, supply chain, commercial and corporate functions. Other listed roles include Vx Finance Director, Pneumo & HPV at GSK (2022–2025), Finance Director, Biologics at GSK (2019–2022), Finance Director, Inhaled Asthma at GSK (2019) and Financial Controller, Global Respiratory and Specialty Therapy Areas at GSK (2017–2019).
Suzanne Behan
LinkedInExperience: Global Treasury & Corporate Insurance - Divisional Controller · Pfizer
Global Treasury & Corporate Insurance - Divisional Controller at Pfizer since 2025. The highlight says the current divisional controller role at Pfizer oversees accounting, disclosures and compliance. Other listed roles include Director, European BioPharma & GBS Divisional Controller at Pfizer (2019–2025), Record to Report Statutory Reporting COE Manager at Pfizer (2013–2019), Statutory Centre of Excellence Lead - GBS Europe at Pfizer (2011–2013) and Senior Manager (Audit and Assurance) - PriceWaterhouseCoopers at PwC (2004–2011).
Thomas Hall
LinkedInExperience: Vice President, Finance Merck Research Laboratories · Merck
Former Vice President, Finance Merck Research Laboratories at Merck (2021–2024). The highlight headline reads Senior Vice President, Finance Merck Research Laboratories at Merck. Also Senior Vice President at Merck since 2024. Other listed roles include VP, Financial Planning & Analysis at Merck (2019–2021), ASSOCIATE VICE PRESIDENT, FINANCIAL PLANNING AND ANALYSIS, CORPORATE FINANCIAL SERVICES at Merck (2016–2018) and Associate Vice President, Business Development, Customer Business Lines at Merck (2014–2016).
Choose the right perspective
Match the person's finance area to your question: R&D or clinical development finance for pipeline and trial budgets, commercial finance and FP&A for launch and product forecasts, and controllers or accounting leaders for reporting and controls. Check whether the relevant role is current or past and whether it covered a country, a therapy area or the whole company.
Questions to take into the conversation
- 01How did you build and defend the budget for an R&D or clinical development portfolio, and what made you cut or keep a program?
- 02How did you forecast a product's commercial performance, and which assumptions such as pricing, access or uptake moved the forecast most?
- 03When R&D and commercial leaders competed for the same money, how did finance frame the tradeoff for decision makers?
Reaching finance professionals in Pharmaceuticals
How can I contact one of these finance professionals in Pharmaceuticals?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 9 companies, including Incyte, Sunovion Pharmaceuticals and ViiV Healthcare, based on profile data retrieved on October 1, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach finance professionals in Pharmaceuticals?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal